8-KOther Events

AMGEN INC 8-K Report (Aug 13, 2002)

Filed August 13, 2002For Securities:AMGN

Summary

This 8-K filing from Amgen Inc. (AMGN) on August 13, 2002, primarily serves to announce the public filing of its Quarterly Report on Form 10-Q for the period ending June 30, 2002. This filing is significant as it marks Amgen's compliance with the new certification requirements mandated by Section 906 of the Sarbanes-Oxley Act of 2002, which became effective earlier that year. Investors can find detailed financial and operational information for the second quarter of 2002 within the accompanying Form 10-Q. The inclusion of the Section 906 certifications underscores Amgen's commitment to enhanced corporate governance and financial transparency. While this 8-K itself does not contain new operational or financial performance data beyond what is presented in the 10-Q, it is a crucial regulatory disclosure indicating the timely submission of the company's quarterly financial statements and the CEO's and CFO's certifications regarding their accuracy and completeness.

Key Highlights

  • 1Amgen Inc. filed its Quarterly Report on Form 10-Q for the period ended June 30, 2002.
  • 2The filing was made on August 13, 2002.
  • 3This 8-K includes the required certifications under Section 906 of the Sarbanes-Oxley Act of 2002.
  • 4These certifications are provided by Amgen's principal executive and financial officers.
  • 5The report signals compliance with new regulatory requirements for financial disclosures.
  • 6No new material financial or operational information is presented in this 8-K itself, but it directs investors to the 10-Q for detailed quarterly results.

Frequently Asked Questions

The primary purpose of this 8-K filing is to inform the public that Amgen Inc. has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2002, and to include the certifications required by Section 906 of the Sarbanes-Oxley Act of 2002.

Amgen's financial results for the second quarter of 2002 are detailed in the accompanying Quarterly Report on Form 10-Q, which was filed with the SEC on August 13, 2002.

The Sarbanes-Oxley Act, enacted in 2002, introduced new requirements for corporate governance and financial reporting. The Section 906 certifications included in this filing mean that Amgen's CEO and CFO have personally certified the accuracy and completeness of the financial statements in the Form 10-Q.

No, this 8-K filing itself does not introduce any new operational or financial performance data. Its purpose is to announce the filing of the 10-Q and to provide the mandatory SOX certifications. Investors should refer to the Form 10-Q for detailed financial and operational information.